July 1, 2024 07:05 AM EDT
Deals
R&D

Ei­sai takes over de­vel­op­ment of ADC af­ter Bris­tol My­ers ends $650M col­lab­o­ra­tion

Katherine Lewin

News Reporter

Due to Bris­tol My­ers Squibb’s port­fo­lio pri­or­i­ti­za­tion ef­forts, Ei­sai is tak­ing back an an­ti­body-drug con­ju­gate that they orig­i­nal­ly teamed up on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times